Search Results for "rapid"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for rapid. Results 101 to 109 of 109 total matches.

Antiviral Drugs for Seasonal Influenza for 2024-2025

   
The Medical Letter on Drugs and Therapeutics • Dec 09, 2024  (Issue 1717)
statement. Pediatrics 2024; 154:e2024068507. 4. CDC. Information for clinicians on rapid diagnostic ...
Influenza is generally a self-limited illness, but pneumonia, respiratory failure, and death can occur, especially in persons at increased risk for influenza complications (see Table 1). Updated information on influenza activity and antiviral resistance is available from the CDC at cdc.gov/flu.
Med Lett Drugs Ther. 2024 Dec 9;66(1717):193-8   doi:10.58347/tml.2024.1717a |  Show IntroductionHide Introduction

Influenza Vaccines for 2025-2026

   
The Medical Letter on Drugs and Therapeutics • Sep 29, 2025  (Issue 1738)
may decline more rapidly.16 Nevertheless, vaccination of older persons has been associated with a reduced ...
Annual vaccination against influenza A and B viruses is recommended in the US for everyone ≥6 months old without a contraindication. Influenza vaccines available in the US for the 2025-2026 season are listed in Table 2.
Med Lett Drugs Ther. 2025 Sep 29;67(1738):153-8   doi:10.58347/tml.2025.1738a |  Show IntroductionHide Introduction

Drugs for Gout

   
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023  (Issue 1688)
-soluble metabolite cleared by the kidneys.27 Infused every two weeks, pegloticase rapidly lowers serum ...
Drugs for gout are used to reduce the pain and inflammation of acute flares, decrease the frequency of exacerbations, and lower serum urate levels to prevent recurrent flares, development of tophi, and joint damage.
Med Lett Drugs Ther. 2023 Oct 30;65(1688):169-75   doi:10.58347/tml.2023.1688a |  Show IntroductionHide Introduction

Drugs for Postmenopausal Osteoporosis

   
The Medical Letter on Drugs and Therapeutics • Jul 08, 2024  (Issue 1706)
antiresorptive drug, typically a bisphosphonate, is recommended to prevent a rapid decline in BMD. Switching ...
Pharmacologic treatment is recommended for postmenopausal women who have bone density T-scores (standard deviations from normal mean values in the spine, femoral neck, total hip, or distal radius) of -2.5 or below, T-scores between -1.0 and -2.5 with a history of fragility (low-trauma) fracture of the hip or spine, or T-scores between -1.0 and -2.5 with a FRAX 10-year probability of ≥3% for hip fracture or ≥20% for major osteoporotic fracture.
Med Lett Drugs Ther. 2024 Jul 8;66(1706):105-12   doi:10.58347/tml.2024.1706a |  Show IntroductionHide Introduction

Drugs for Chronic Heart Failure

   
The Medical Letter on Drugs and Therapeutics • May 26, 2025  (Issue 1729)
symptomatic relief of pulmonary and peripheral edema more rapidly than other drugs used for treatment of HF ...
Pharmacologic management of chronic heart failure (HF) is primarily determined by the patient's left ventricular ejection fraction (LVEF) and severity of symptoms. Patients with chronic HF who have an LVEF ≤40% are considered to have heart failure with reduced ejection fraction (HFrEF) and those with an LVEF ≥50% are considered to have heart failure with preserved ejection fraction (HFpEF). Patients with an LVEF of 41-49% have heart failure with mildly reduced or mid-range ejection fraction.
Med Lett Drugs Ther. 2025 May 26;67(1729):81-8   doi:10.58347/tml.2025.1729a |  Show IntroductionHide Introduction

Drugs for Irritable Bowel Syndrome

   
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025  (Issue 1721)
, monosaccharides, and polyols) may reduce IBS symptoms.5-7 FODMAPs are poorly absorbed, rapidly fermented, short ...
Irritable bowel syndrome (IBS) is a common disorder characterized by recurrent abdominal pain and altered bowel habits, often accompanied by bloating. IBS is classified by its predominant bowel symptom: constipation (IBS-C), diarrhea (IBS-D), mixed type (IBS-M), or unclassified (IBS-U). Since the exact cause of IBS is unknown, the goal of treatment is symptom control. Some over-the-counter (OTC) products and prescription drugs for IBS are listed in Tables 1-4. The safety of these drugs during pregnancy and lactation is described in Table 5 (online only).
Med Lett Drugs Ther. 2025 Feb 3;67(1721):17-24   doi:10.58347/tml.2025.1721a |  Show IntroductionHide Introduction

Drugs for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022  (Issue 1663)
in patients with CKD. Both drugs are rapidly absorbed and cleared; plasma levels of insulin peak 30-60 ...
Diet, exercise, and weight loss can improve glycemic control, but almost all patients with type 2 diabetes require antihyperglycemic drug therapy. Treating to a target A1C of <7% while minimizing hypoglycemia is recommended to prevent microvascular complications of diabetes (retinopathy, nephropathy, and neuropathy). An A1C target of <8% may be appropriate for some older patients.
Med Lett Drugs Ther. 2022 Nov 14;64(1663):177-84 |  Show IntroductionHide Introduction

Drugs for Migraine

   
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023  (Issue 1678)
) for treatment of migraine; it has a rapid onset of action (~15 minutes).5 Products that contain butalbital ...
An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine pain without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine in most patients without vascular disease. Treatment of pain when it is still mild to moderate in intensity improves headache response and reduces the risk of recurrence.
Med Lett Drugs Ther. 2023 Jun 12;65(1678):89-96   doi:10.58347/tml.2023.1678a |  Show IntroductionHide Introduction

Comparison Chart: Some Drugs for HFrEF

   
The Medical Letter on Drugs and Therapeutics • May 26, 2025  (Issue 1729)
and peripheral edema more rapidly than other drugs used for treatment of heart failure . Bumetanide ...
View the Comparison Chart: Some Drugs for HFrEF
Med Lett Drugs Ther. 2025 May 26;67(1729):e1-15   doi:10.58347/tml.2025.1729b |  Show IntroductionHide Introduction